应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SNY 赛诺菲安万特
交易中 07-24 11:32:57 EDT
43.37
+0.01
+0.01%
最高
43.45
最低
42.94
成交量
125.68万
今开
43.17
昨收
43.36
日振幅
1.19%
总市值
1,038亿
流通市值
937.12亿
总股本
23.94亿
成交额
5,444万
换手率
0.06%
流通股本
21.61亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|赛诺菲盘前下跌3.23%,报43.4美元
行情直击 · 07-14
异动解读|赛诺菲盘前下跌3.23%,报43.4美元
异动解读|赛诺菲夜盘下跌3.23%,报42.58美元
行情直击 · 07-14
异动解读|赛诺菲夜盘下跌3.23%,报42.58美元
异动解读|赛诺菲安万特盘中上涨3.19%,制药板块集体走强叠加罕见病管线利好驱动反弹
行情直击 · 07-02
异动解读|赛诺菲安万特盘中上涨3.19%,制药板块集体走强叠加罕见病管线利好驱动反弹
异动解读|赛诺菲安万特盘中下跌3.01%,欧盟反垄断调查叠加研发管线隐忧持续承压
行情直击 · 07-02
异动解读|赛诺菲安万特盘中下跌3.01%,欧盟反垄断调查叠加研发管线隐忧持续承压
赛诺菲(SNY)罕见病药物临床试验全线达标 拟申报婴幼儿适应症上市许可
金吾财讯 · 06-30
赛诺菲(SNY)罕见病药物临床试验全线达标 拟申报婴幼儿适应症上市许可
异动解读|赛诺菲安万特盘中下跌3.11%,核心在研药III期试验失败余震持续
行情直击 · 06-18
异动解读|赛诺菲安万特盘中下跌3.11%,核心在研药III期试验失败余震持续
异动解读|赛诺菲安万特盘中上涨4.59%,全球首创新药获FDA优先审评
行情直击 · 06-04
异动解读|赛诺菲安万特盘中上涨4.59%,全球首创新药获FDA优先审评
异动解读|赛诺菲安万特盘前上涨3.09%,全球首创新药获FDA优先审评
行情直击 · 06-04
异动解读|赛诺菲安万特盘前上涨3.09%,全球首创新药获FDA优先审评
赛诺菲(SNY.US)全球首创新药申报上市
智通财经 · 05-28
赛诺菲(SNY.US)全球首创新药申报上市
跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手
21世纪经济报道 · 05-08
跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手
跨国药企业绩大爆发,集体加仓中国
21世纪经济报道 · 05-07
跨国药企业绩大爆发,集体加仓中国
靠Dupixent还能“躺赢”多久?赛诺菲(SNY.US)业绩报喜难掩研发焦虑 股价承压静待新帅破局
智通财经 · 04-23
靠Dupixent还能“躺赢”多久?赛诺菲(SNY.US)业绩报喜难掩研发焦虑 股价承压静待新帅破局
辉瑞、赛诺菲押注!AI制药估值10亿美元,22款药物进入临床!
智药局 · 04-16
辉瑞、赛诺菲押注!AI制药估值10亿美元,22款药物进入临床!
财报前瞻|赛诺菲安万特本季度营收预计增10.21%,机构观点偏正面
财报Agent · 04-16
财报前瞻|赛诺菲安万特本季度营收预计增10.21%,机构观点偏正面
还没进临床,就融了10亿:华人创立眼科biotech为何屡获巨头押注?
药融圈 · 03-12
还没进临床,就融了10亿:华人创立眼科biotech为何屡获巨头押注?
赛诺菲换帅,任命默克KGaA首席执行官为下一任CEO
环球市场播报 · 02-13
赛诺菲换帅,任命默克KGaA首席执行官为下一任CEO
65岁西班牙人成为赛诺菲史上首位女CEO,为何股价下跌
第一财经 · 02-13
65岁西班牙人成为赛诺菲史上首位女CEO,为何股价下跌
研发失速叠加特朗普变量 赛诺菲(SNY.US)新CEO加里霍面临双重挑战
智通财经 · 02-13
研发失速叠加特朗普变量 赛诺菲(SNY.US)新CEO加里霍面临双重挑战
赛诺菲(SNY.US)突发换帅:研发“哑火”成“催命符”,默沙东高管火线接手
智通财经 · 02-12
赛诺菲(SNY.US)突发换帅:研发“哑火”成“催命符”,默沙东高管火线接手
明星药物Dupixent销售额再创新高!赛诺菲(SNY.US)Q4盈利超预期
智通财经 · 01-29
明星药物Dupixent销售额再创新高!赛诺菲(SNY.US)Q4盈利超预期
加载更多
公司概况
公司名称:
赛诺菲安万特
所属市场:
NASDAQ
上市日期:
--
主营业务:
Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司,专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织:DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。
发行价格:
--
{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":43.365,"timestamp":1784907174000,"preClose":43.36,"halted":0,"volume":1256761,"delay":0,"changeRate":0.00011531365313659036,"floatShares":2161000000,"shares":2394000000,"eps":3.575486,"marketStatus":"交易中","change":0.005,"latestTime":"07-24 11:32:57 EDT","open":43.17,"high":43.45,"low":42.935,"amount":54437085.311224,"amplitude":0.011877,"askPrice":43.36,"askSize":58,"bidPrice":43.35,"bidSize":220,"shortable":3,"etf":0,"ttmEps":3.575486,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784923200000},"marketStatusCode":2,"adr":1,"adrRate":0.5,"listingDate":1025496000000,"exchange":"NASDAQ","adjPreClose":43.36,"dividendRate":0.055288,"preHourTrading":{"tag":"盘前","latestPrice":43.17,"preClose":43.36,"latestTime":"09:29 EDT","volume":64817,"amount":2772950.077472,"timestamp":1784899799000,"change":-0.19,"changeRate":-0.004382,"amplitude":0.017758},"postHourTrading":{"tag":"盘后","latestPrice":43.44,"preClose":43.36,"latestTime":"19:52 EDT","volume":21457,"amount":933601.8704,"timestamp":1784850734655,"change":0.08,"changeRate":0.001845,"amplitude":0.001845},"volumeRatio":1.124823,"impliedVol":0.3189,"impliedVolPercentile":0.7211},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"1163046670","title":"异动解读|赛诺菲盘前下跌3.23%,报43.4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163046670","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163046670?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:03","pubTimestamp":1784016232,"startTime":"0","endTime":"0","summary":"7月14日,赛诺菲盘前下跌3.23%,报43.4美元/股,成交额1610.54美元。赛诺菲所在的制药行业中,个股表现分化,其中辉瑞涨0.12%,强生涨0.04%,礼来跌0.07%,施贵宝跌0.27%,阿斯利康跌1.74%。Sanofi是一家全球领先的医疗保健公司,专注于患者需求并从事治疗解决方案的研究、开发、制造和营销,核心产品包括DUPIXENT、神经病学与免疫学、罕见病、肿瘤学、疫苗等业务板块。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143282410","title":"异动解读|赛诺菲夜盘下跌3.23%,报42.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143282410","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143282410?lang=zh_cn&edition=full","pubTime":"2026-07-14 13:33","pubTimestamp":1784007235,"startTime":"0","endTime":"0","summary":"7月14日,赛诺菲夜盘下跌3.23%,报42.58美元/股,成交额1.15万美元。赛诺菲所在的制药行业中,个股表现分化,其中礼来涨0.14%,施贵宝涨0.2%,辉瑞持平,阿斯利康跌0.08%,强生跌0.22%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179667203","title":"异动解读|赛诺菲安万特盘中上涨3.19%,制药板块集体走强叠加罕见病管线利好驱动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1179667203","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179667203?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:19","pubTimestamp":1783001990,"startTime":"0","endTime":"0","summary":"7月2日,赛诺菲安万特盘中上涨3.19%,报42.95美元/股,成交额2471.59万美元。此前该股因欧盟反垄断调查消息一度承压,当日盘中出现明显反弹。消息面上,制药板块整体走强,阿斯利康涨4.67%,诺和诺德涨3.58%,礼来涨2.21%,行业情绪回暖带动资金回流。同时,赛诺菲近期管线进展积极,其罕见病药物Nexviazyme针对婴儿型庞贝病的三期临床试验顺利达成主要终点,公司计划向美国监管机构提交上市申请,进一步拓宽适用人群。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152994480","title":"异动解读|赛诺菲安万特盘中下跌3.01%,欧盟反垄断调查叠加研发管线隐忧持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1152994480","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152994480?lang=zh_cn&edition=full","pubTime":"2026-07-02 01:31","pubTimestamp":1782927110,"startTime":"0","endTime":"0","summary":"7月2日,赛诺菲安万特盘中下跌3.01%,报41.375美元/股,成交额1.16亿美元。消息面上,欧盟委员会于6月26日正式对赛诺菲发起反垄断调查,指控其通过误导性宣传活动诋毁竞争对手CSL Seqirus的流感疫苗Fluad,以推动自家Efluelda疫苗销量,涉嫌滥用市场支配地位。欧盟此前已于去年9月对赛诺菲德法办公地点进行突击搜查,此次调查升级对公司声誉及业务运营构成持续压力。制药行业整体承压,礼来跌1.51%,默沙东跌1.70%,赛诺菲跌幅明显超出同业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555292","title":"赛诺菲(SNY)罕见病药物临床试验全线达标 拟申报婴幼儿适应症上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555292","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647555292?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:00","pubTimestamp":1782820825,"startTime":"0","endTime":"0","summary":"金吾财讯 | 赛诺菲 于周二公布旗下药物Nexviazyme最新临床研究成果,该药物针对6个月及以下、未经治疗的婴儿型庞贝病患儿开展三期临床试验,顺利达成预设主要终点。基于本次完整且达标的三期临床数据,赛诺菲计划正式向美国监管机构提交申请,争取获批用于治疗婴儿型庞贝病,进一步拓宽药物的临床适用人群范围。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4007","BK4585","IPOS","SNY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192521900","title":"异动解读|赛诺菲安万特盘中下跌3.11%,核心在研药III期试验失败余震持续","url":"https://stock-news.laohu8.com/highlight/detail?id=1192521900","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192521900?lang=zh_cn&edition=full","pubTime":"2026-06-18 03:17","pubTimestamp":1781723834,"startTime":"0","endTime":"0","summary":"6月18日,赛诺菲安万特盘中下跌3.11%,报42.68美元/股,成交额2.9亿美元。消息面上,公司于6月10日宣布终止核心在研药物riliprubart用于难治性慢性炎性脱髓鞘性多发性神经病的III期MOBILIZE研究,独立数据监查委员会中期分析显示该研究不太可能达到预设疗效终点。该药物曾被视为赛诺菲重要管线资产,此次失败打乱了公司依靠新产品接棒增长的计划。在王牌药物Dupixent面临专利悬崖压力下,研发管线不确定性持续压制股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123049374","title":"异动解读|赛诺菲安万特盘中上涨4.59%,全球首创新药获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1123049374","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123049374?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:06","pubTimestamp":1780581974,"startTime":"0","endTime":"0","summary":"6月4日,赛诺菲安万特盘中上涨4.59%,报44.535美元/股,成交额2711.19万美元。消息面上,赛诺菲宣布其全球首创新药Venglustat的上市申请获FDA受理并予以优先审评,用于治疗III型戈谢病,FDA目标审批日期为11月25日。若获批,Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案。此外,赛诺菲还落地了JAK/ROCK双靶点抑制剂的临床应用,进一步拓展血液与移植领域创新布局,多重管线利好提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137888141","title":"异动解读|赛诺菲安万特盘前上涨3.09%,全球首创新药获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1137888141","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137888141?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:05","pubTimestamp":1780563940,"startTime":"0","endTime":"0","summary":"6月4日,赛诺菲安万特盘前上涨3.09%,报43.68美元/股,成交额35.62万美元。消息面上,赛诺菲近日宣布其全球首创新药Venglustat的上市申请获FDA受理并予以优先审评,用于治疗III型戈谢病。FDA目标审批日期为11月25日。若获批,Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案。此外,赛诺菲还落地了JAK/ROCK双靶点抑制剂的临床应用,进一步拓展血液与移植领域创新布局,多重管线利好提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669690","title":"赛诺菲(SNY.US)全球首创新药申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638669690?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:15","pubTimestamp":1779974123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,5月28日,赛诺菲宣布Venglustat的上市申请获得FDA受理并予以优先审评,用于治疗III型戈谢病。如果获批,Venglustat将成为美国首个针对GD3相关进行性神经系统表现的治疗方案,并扩充赛诺菲为溶酶体贮积病患者提供的治疗方案。GSLs的异常积累会导致细胞功能障碍。FDA此次受理主要是基于III期LEAP2MONO研究的积极结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1574","SNY","IPOS","BK4588","BK1161","BK4007","06978","IE00BFXG1179.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410627","title":"跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410627","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633410627?lang=zh_cn&edition=full","pubTime":"2026-05-08 07:52","pubTimestamp":1778197920,"startTime":"0","endTime":"0","summary":"【跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手】有券商医药行业分析师对21世纪经济报道记者表示,当前跨国药企的业绩已高度“超级重磅药化”,手握“王牌”产品足以决定公司的增长、估值乃至战略走向。纵观财报数据,一个清晰的信号也正在浮现:在专利悬崖、政策博弈与市场竞争的多重挑战中,如何深度挖掘并战略性运营核心大单品,已从“增长选择”演变为“生存命题”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083730569459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083730569459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1941712264.USD","LU1983299246.USD","LU0070302665.USD","LU1035773651.USD","NVOH","SG9999002232.USD","IE00B4R5TH58.HKD","LU2360032135.SGD","LU2023250843.SGD","LU0203347892.USD","IE00BZ1G4Q59.USD","LU1917777945.USD","LU1989771016.USD","LU1037948897.HKD","LU2112291526.USD","LU2023250504.SGD","SG9999015341.SGD","SNY","LU0320765489.SGD","LU1941712348.USD","IE00BBT3K403.USD","BK4585","LU1093756168.USD","BK4559","LU2125154778.USD","LU0130517989.USD","IE00BN8TJ469.HKD","IE00BKVL7J92.USD","LU0208291251.USD","SG9999015358.SGD","LU0265550359.USD","IE00BLSP4452.SGD","LU0211331839.USD","LU1116320737.USD","LU1116320901.HKD","SG9999014542.SGD","LU1066051225.USD","BK4534","LU1066051498.USD","MRK","LU1069347547.HKD","LU2468319806.SGD","SG9999014575.USD","SG9999014567.USD","SGXZ57979304.SGD","SG9999014559.SGD","LLY","SG9999002224.SGD","LU1066051811.HKD","LU0320765646.SGD","BK4533","LU2324357040.USD","IE00BSNM7G36.USD","LU0985320562.USD","LU1989772840.SGD","LU1929549753.HKD","LU1934455277.USD","IE00BJJMRZ35.SGD","NVOX","LU0965508806.USD","IE0002141913.USD","LU0289739699.SGD","LU1093756325.SGD","SG9999001176.USD","IE00B1BXHZ80.USD","LU0868494708.USD","LU1291159041.SGD","LU1934455194.USD","LU1037948541.HKD","LU0098860793.USD","LU0859254822.USD","LU1066053197.SGD","LU0648001328.SGD","LU0965509101.SGD","LU1934455863.HKD","SG9999001440.SGD","LU0058720904.USD","LU0477156953.USD","LU0006306889.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU2491049909.HKD","LU0238689110.USD","LU0130102774.USD","LU0265550946.USD","LU2361044865.SGD","BK4007","BK4532","LU0432979614.USD","LU1974910355.USD","LU0861579265.USD","LU2361045086.USD","IE00BFTCPJ56.SGD","LU2106854487.HKD","LU2361044949.HKD","BK4516","BK4588","LU0868494617.USD","SG9999001176.SGD","LU0122379950.USD","LU1989772923.USD","LU2491050154.USD","LU0942090050.USD","LU1061106388.HKD","LU0980610538.SGD","BK4550","LU2125154935.USD","LU0965509283.SGD","LU1201861249.SGD","LU2357627491.SGD","LU0203345920.USD","LU0266013472.USD","LU2089984988.USD","LU0965509010.AUD","IE0009355771.USD","NVO","LU1571399168.USD","LU1057294990.SGD","LU1585245621.USD","SG9999013999.USD","LU0154236417.USD","LU1699723380.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1430594728.SGD","LU0106261372.USD","LU1162221912.USD","LU2461242641.AUD","LU2491050071.SGD","IE00B2B36J28.USD","BK4599","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发,集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 2026年第一季度,全球制药巨头的业绩版图再度刷新。 有券商医药行业分析师对21世纪经济报道记者表示,当前跨国药企的业绩已高度“超级重磅药化”,手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道,已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0648001328.SGD","SG9999002232.USD","LU0477156953.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0859254822.USD","LU2112291526.USD","LU1941712264.USD","BK4550","LU1116320737.USD","LU2023250504.SGD","LU1430594728.SGD","LU0980610538.SGD","SG9999001176.USD","LU1069347547.HKD","LU2491050071.SGD","LU1066051498.USD","LU1057294990.SGD","LU0070302665.USD","LU0208291251.USD","LU2125154935.USD","LU2106854487.HKD","LU1037948897.HKD","MEURmain","AZN","LU2360032135.SGD","IE00BN8TJ469.HKD","IE00BKVL7J92.USD","LU0098860793.USD","LU2361044949.HKD","LU0106261372.USD","LU0265550946.USD","LU1066051225.USD","SG9999014567.USD","LU1917777945.USD","LU1035773651.USD","BK4533","LU2491049909.HKD","LU0868494617.USD","LU1116320901.HKD","LU1989772923.USD","BK4007","SG9999002224.SGD","LU1989771016.USD","IE000M9KFDE8.USD","BK4588","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","LLY","LU0942090050.USD","LU2125154778.USD","LU2461242641.AUD","EUO","LU0203345920.USD","LU0234572021.USD","BK4532","BMY","LU0058720904.USD","SNY","IE00BZ1G4Q59.USD","LU0265550359.USD","LU0289739699.SGD","LU0203347892.USD","LU1093756325.SGD","LU0965509010.AUD","LU1974910355.USD","SG9999001440.SGD","BK4559","LU0130102774.USD","LU1989772840.SGD","LU1929549753.HKD","BK4599","LU0266013472.USD","SG9999014559.SGD","LU1571399168.USD","LU0965508806.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1061106388.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0238689110.USD","LU0320765646.SGD","BK4516","LU1037948541.HKD","LU0965509283.SGD","LU1066053197.SGD","NVS","LU1699723380.USD","LU1066051811.HKD","IE00BJT1NW94.SGD","MRK","LU0985320562.USD","LU1983299246.USD","EURmain","SG9999013999.USD","LU1162221912.USD","SG9999014575.USD","LU1934455277.USD","LU1934455863.HKD","NVOH","LU2468319806.SGD","BK4534","LU0211331839.USD","LU1093756168.USD","LU0130517989.USD","LU1291159041.SGD","SG9999001176.SGD","SG9999014542.SGD","LU0868494708.USD","LU0432979614.USD","LU2361045086.USD","IE00BSNM7G36.USD","IE00B4R5TH58.HKD","LU2357627491.SGD","LU0154236417.USD","BK4585","IE00B1BXHZ80.USD","LU1585245621.USD","LU2361044865.SGD","LU2089984988.USD","SG9999015341.SGD","LU1934455194.USD","LU2491050154.USD","LU1941712348.USD","FXE","LU1201861249.SGD","SG9999015358.SGD","LU0320765489.SGD","IE00B2B36J28.USD","LU0122379950.USD","LU0965509101.SGD","IE0009355771.USD","LU0861579265.USD","NVO","LU0006306889.USD","NVOX","LU2324357040.USD","LU2023250843.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629883659","title":"靠Dupixent还能“躺赢”多久?赛诺菲(SNY.US)业绩报喜难掩研发焦虑 股价承压静待新帅破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629883659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629883659?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:35","pubTimestamp":1776929736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,法国制药巨头赛诺菲周四公布了2026年第一季度财报。不过,市场焦点已迅速转向Garijo将如何应对研发管线青黄不接及Dupixent未来专利到期的战略挑战。Dupixent的专利将于下个十年初到期,而赛诺菲迄今尚未拿出足以填补该药物收入缺口的明确替代方案。在过去12个月里,受一系列好坏参半甚至负面的临床试验结果拖累,赛诺菲股价已累计下跌约13%。赛诺菲还提到了公司短期内可能面临的逆风。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IE00BFXG1179.USD","BK4588","BK4007","SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291839","title":"辉瑞、赛诺菲押注!AI制药估值10亿美元,22款药物进入临床!","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291839","media":"智药局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627291839?lang=zh_cn&edition=full","pubTime":"2026-04-16 18:03","pubTimestamp":1776333780,"startTime":"0","endTime":"0","summary":"AI制药再迎重磅融资!近日,美国波士顿AI制药公司Alloy Therapeutics宣布完成4000万美元E轮融资。本轮融资后,公司最新一轮融资估值为10亿美元。截至目前,Alloy已与200多家合作伙伴建立合作。其中22个已进入临床开发阶段,2个处于3期临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhusviy2842117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999002224.SGD","IE00B19Z3581.USD","LU1894683264.USD","BK4581","LU0985481810.HKD","SNY","BK4588","LU0321505868.SGD","SG9999002232.USD","LU1066051498.USD","BK1191","LU0058720904.USD","SG9999001176.USD","LU1066053197.SGD","BK4533","LU0289739699.SGD","SG9999003800.SGD","BK1574","IE00BLSP4452.SGD","LU0456855351.SGD","SG9999011175.SGD","BK4592","BK4550","LU1057294990.SGD","LU1894683348.USD","IE000M9KFDE8.USD","SG9999013999.USD","BK4534","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0306806265.USD","LU0122379950.USD","BK4007","LU0306807586.USD","LU0321505439.SGD","PFE","LU0170899867.USD","BK4585","BK4568","BK4599","LU1023059063.AUD","LU0225771236.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","IE0002270589.USD","LU0225284248.USD","LU0234572021.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1134454624","title":"财报前瞻|赛诺菲安万特本季度营收预计增10.21%,机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1134454624","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134454624?lang=zh_cn&edition=full","pubTime":"2026-04-16 08:23","pubTimestamp":1776299037,"startTime":"0","endTime":"0","summary":"赛诺菲安万特将于2026年04月23日美股盘前发布季度财报,市场聚焦营收与盈利修复节奏及费用结构走势。市场一致预期本季度赛诺菲安万特营收为120.69亿美元,同比增10.21%;调整后每股收益为1.03美元,同比增7.65%;同时,息税前利润预计为32.46亿美元,同比增11.84%;当前一致预期未提供本季度的毛利率与净利润或净利率的具体预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|赛诺菲安万特本季度营收预计增10.21%,机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618853906","title":"还没进临床,就融了10亿:华人创立眼科biotech为何屡获巨头押注?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618853906","media":"药融圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618853906?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:34","pubTimestamp":1773279273,"startTime":"0","endTime":"0","summary":"CTX203旨在稳定一种名为ABCA1的蛋白质的表达水平,这种蛋白质与视网膜细胞中的脂质运输过程密切相关。合作初期将聚焦于AMD,并有望拓展至其他眼部疾病。根据协议条款,Character Bio已获得一笔首付款及年度研究资金,并有资格获得与后续开发及销售相关的里程碑付款,以及未来产品销售额的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823421416.USD","BK4554","IE00B5949003.HKD","AMDL","IE00BMPRXN33.USD","LU2054465674.USD","AMDD","LU1951200564.SGD","IE00BMPRXR70.SGD","BK4512","RHHBY","LU2458330169.SGD","AMYY","LU0642271901.SGD","AMUU","IE0009356076.USD","LU2098885051.SGD","LU0198837287.USD","LU0979878070.USD","BK4612","LU1861559042.SGD","BK4585","LU1316542783.SGD","BK4529","LU1303367103.USD","SNY","APLS","BK4532","LU2931357623.SGD","LU2089985449.USD","BK4605","LU0823434583.USD","LU1880398471.USD","LU0109392836.USD","LU0127658192.USD","AMDW","LU2355687059.USD","LU2250418816.HKD","AMDU","BK4588","BK4534","LU0889565833.HKD","LU2264538146.SGD","DAMD","LU0082616367.USD","AMD","AMDY","BK4573","LU2458330243.SGD","BK4566","LU1923623000.USD","LU2360106780.USD","BK4543","LU0081259029.USD","LU0056508442.USD","LU1861558580.USD","BHC","AMDG","LU0390134368.USD","BK4141","LU1880398554.USD","LU1989764664.SGD","LU0719512351.SGD","LU1064131342.USD","LU0274383776.USD","LU1803068979.SGD","LU0823434740.USD","BK4614","LU1852331112.SGD","PFE","LU1988902786.USD","LU1951198990.SGD","BK4575","IE0004445239.USD","LU1242518931.SGD","LU1242518857.USD","LU0823421333.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2611169888","title":"赛诺菲换帅,任命默克KGaA首席执行官为下一任CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611169888","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611169888?lang=zh_cn&edition=full","pubTime":"2026-02-13 23:51","pubTimestamp":1770997860,"startTime":"0","endTime":"0","summary":"赛诺菲安万特(SNY)周五早盘下跌1.9%。在产品线受挫和股价疲软之际,该公司罢免了保罗·哈德森(Paul Hudson),任命德国默克KGaA(XETRA:MRK)的CEO贝伦·加里霍(Belén Garijo)为其下一任首席执行官。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-13/doc-inhmszca5619561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BLSP4239.USD","LU1057294990.SGD","SG9999013999.USD","SG9999015341.SGD","SG9999001176.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0965509101.SGD","SG9999015358.SGD","LU1934455863.HKD","BK4534","LU1929549753.HKD","LU1061106388.HKD","LU1037948541.HKD","SG9999014542.SGD","LU2023250504.SGD","LU0106261372.USD","LU2112291526.USD","LU1201861249.SGD","LU0006306889.USD","LU0070302665.USD","LU1934455194.USD","SG9999014575.USD","LU0265550359.USD","LU0320765646.SGD","SG9999002224.SGD","LU0098860793.USD","LU2324357040.USD","LU0203345920.USD","IE00BBT3K403.USD","LU2125154778.USD","BK4533","LU1571399168.USD","SGXZ57979304.SGD","LU1066051498.USD","LU1989772840.SGD","LU0861579265.USD","LU1069347547.HKD","BK4007","LU0238689110.USD","LU1983299246.USD","LU1941712264.USD","IE00BJT1NW94.SGD","LU0130517989.USD","SG9999001440.SGD","LU0058720904.USD","LU0234572021.USD","IE00BLSP4452.SGD","SG9999002232.USD","LU0208291251.USD","LU1989771016.USD","LU0648001328.SGD","LU1989772923.USD","LU2125154935.USD","LU2361044865.SGD","LU1116320737.USD","LU0432979614.USD","IE000M9KFDE8.USD","LU0203347892.USD","IE00B4R5TH58.HKD","BK4585","LU1974910355.USD","LU2360032135.SGD","SNY","LU2461242641.AUD","SG9999014559.SGD","LU1023059063.AUD","LU1093756168.USD","LU1116320901.HKD","LU0980610538.SGD","BK4588","LU1917777945.USD","LU1066051225.USD","LU1430594728.SGD","LU1941712348.USD","LU0266013472.USD","LU1093756325.SGD","BK4516","BK4559","IE0009355771.USD","LU2361044949.HKD","LU0965509010.AUD","LU0477156953.USD","LU0289739699.SGD","BK4550","IE00B2B36J28.USD","LU1934455277.USD","SG9999014567.USD","LU1066053197.SGD","LU0130102774.USD","LU0122379950.USD","LU1162221912.USD","LU2468319806.SGD","IE00BSNM7G36.USD","LU0265550946.USD","SG9999001176.SGD","LU0965508806.USD","LU2106854487.HKD","LU0965509283.SGD","LU2023250843.SGD","MRK","LU1585245621.USD","IE00BN8TJ469.HKD","IE00B1BXHZ80.USD","LU1291159041.SGD","LU0985320562.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU2361045086.USD","LU1035773651.USD","LU0211331839.USD","LU1699723380.USD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611113254","title":"65岁西班牙人成为赛诺菲史上首位女CEO,为何股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2611113254","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611113254?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:44","pubTimestamp":1770972259,"startTime":"0","endTime":"0","summary":"当地时间2月12日,法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗(PaulHudson)的任期,并任命65岁的现默克CEO、西班牙人葛丽鹤(BelénGarijo)为CEO。葛丽鹤也将成为赛诺菲史上首位女性CEO,她将于2026年4月29日集团年度股东大会结束后正式履职。不过在这一消息公布后,当天赛诺菲股价下跌4.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602133650435555.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133650435555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0238689110.USD","SG9999013999.USD","LU2361044865.SGD","LU1057294990.SGD","LU1571399168.USD","LU0130517989.USD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU1941712264.USD","IE00BJT1NW94.SGD","LU0098860793.USD","LU0320765489.SGD","BK4585","SG9999001440.SGD","IE00BSNM7G36.USD","LU0070302665.USD","LU0130102774.USD","IE00BBT3K403.USD","LU2106854487.HKD","SG9999001176.SGD","LU2125154935.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU2361044949.HKD","LU1037948541.HKD","SG9999014559.SGD","LU0861579265.USD","LU1066053197.SGD","SG9999002224.SGD","LU1069347547.HKD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1934455863.HKD","LU1066051225.USD","LU0058720904.USD","SG9999014575.USD","LU0965509010.AUD","LU1929549753.HKD","LU1974910355.USD","LU0980610538.SGD","LU0266013472.USD","LU1291159041.SGD","SGXZ57979304.SGD","LU1037948897.HKD","LU1983299246.USD","LU0203345920.USD","LU0648001328.SGD","LU1066051498.USD","LU2125154778.USD","LU2324357040.USD","LU2023250843.SGD","LU1035773651.USD","SG9999015341.SGD","LU0265550946.USD","LU2360032135.SGD","LU1116320737.USD","LU1093756325.SGD","LU2361045086.USD","LU1430594728.SGD","LU1201861249.SGD","LU2089984988.USD","LU0985320562.USD","LU1917777945.USD","BK4534","LU0477156953.USD","LU2461242641.AUD","SNY","LU1934455194.USD","SG9999014567.USD","LU0006306889.USD","IE000M9KFDE8.USD","LU0965508806.USD","BK4559","IE00BFTCPJ56.SGD","LU1116320901.HKD","LU1941712348.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU2112291526.USD","LU2468319806.SGD","IE00BLSP4239.USD","BK4533","LU0234572021.USD","LU1934455277.USD","LU0320765646.SGD","IE0009355771.USD","LU1699723380.USD","LU0122379950.USD","LU1585245621.USD","LU0106261372.USD","LU1061106388.HKD","LU0965509101.SGD","BK4007","LU0265550359.USD","LU0965509283.SGD","BK4550","LU1989772923.USD","SG9999014542.SGD","IE00B1BXHZ80.USD","LU0432979614.USD","BK4516","IE0002141913.USD","LU1989772840.SGD","LU0208291251.USD","SG9999015358.SGD","SG9999002232.USD","LU2023250504.SGD","LU0203347892.USD","LU0211331839.USD","LU1989771016.USD","BK4588","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611332139","title":"研发失速叠加特朗普变量 赛诺菲(SNY.US)新CEO加里霍面临双重挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2611332139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611332139?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:47","pubTimestamp":1770968831,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,法国制药巨头赛诺菲即将上任的首席执行官、65 岁的贝伦·加里霍面临一项重大任务:赢得投资者支持,加快这家法国公司停滞不前的药物研发进程,并在美国总统唐纳德·特朗普执政期间应对疫苗怀疑论。据了解,赛诺菲于2月12日突然宣布首席执行官保罗·哈德森将于本月离职,由默克集团高管贝伦·加里霍于 4 月接任。加里霍未立即回应置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","SNY","BK4588","BK4007","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610944495","title":"赛诺菲(SNY.US)突发换帅:研发“哑火”成“催命符”,默沙东高管火线接手","url":"https://stock-news.laohu8.com/highlight/detail?id=2610944495","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610944495?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:30","pubTimestamp":1770892211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,赛诺菲于2月12日突然宣布首席执行官Paul Hudson下课,由默沙东集团高管贝伦·加里霍接任。加里霍:熟悉赛诺菲的“空降兵”加里霍在默沙东的任期即将结束,这位西班牙高管曾在赛诺菲任职15载,对后者熟稔于心。赛诺菲在声明中表示,她将“以更严苛的执行力推进赛诺菲战略落地”,并补充称,其首要任务是提升研发板块的产出效能、治理水平与创新能力。Paul Hudson的最后一个工作日定于2月17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1983299246.USD","LU2023250843.SGD","LU0070302665.USD","LU2089984988.USD","LU0477156953.USD","LU2361044949.HKD","LU0266013472.USD","LU1934455194.USD","SG9999001176.USD","LU1162221912.USD","LU0130102774.USD","IE00BLSP4239.USD","LU1066051811.HKD","SNY","IE00BFXG1179.USD","SG9999014559.SGD","LU0320765489.SGD","BK4550","LU2106854487.HKD","IE0002141913.USD","LU1941712348.USD","LU0130517989.USD","LU1989772923.USD","LU2360032135.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","LU0006306889.USD","LU1069347547.HKD","LU0648001328.SGD","LU0203347892.USD","LU2361045086.USD","IE000M9KFDE8.USD","LU0320765646.SGD","LU2461242641.AUD","BK4007","BK4534","LU2125154778.USD","LU1989772840.SGD","LU1037948541.HKD","LU1974910355.USD","BK4559","SG9999001440.SGD","SGXZ57979304.SGD","LU0980610538.SGD","LU1201861249.SGD","SG9999002232.USD","LU0098860793.USD","LU1093756325.SGD","BK4588","LU1066053197.SGD","SG9999014542.SGD","LU1035773651.USD","IE0009355771.USD","SG9999013999.USD","LU0106261372.USD","LU0265550359.USD","IE00B2B36J28.USD","SG9999015341.SGD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU1093756168.USD","LU0238689110.USD","LU1934455277.USD","SG9999001176.SGD","SG9999015358.SGD","LU1061106388.HKD","LU1066051498.USD","LU0122379950.USD","LU2324357040.USD","LU1116320737.USD","LU1066051225.USD","LU0203345920.USD","LU1934455863.HKD","SG9999014575.USD","LU1917777945.USD","LU2125154935.USD","LU0965509101.SGD","LU1291159041.SGD","LU0265550946.USD","LU0234572021.USD","LU0965509283.SGD","LU0965508806.USD","LU1116320901.HKD","LU0432979614.USD","LU2468319806.SGD","LU1430594728.SGD","LU2361044865.SGD","BK4516","LU0289739699.SGD","LU0985320562.USD","LU0208291251.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1941712264.USD","SG9999014567.USD","LU0861579265.USD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0211331839.USD","LU1699723380.USD","LU1929549753.HKD","LU2112291526.USD","LU1037948897.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4533","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","MRK","LU0965509010.AUD","LU1057294990.SGD","LU2023250504.SGD","LU1989771016.USD","BK4585","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607704988","title":"明星药物Dupixent销售额再创新高!赛诺菲(SNY.US)Q4盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704988","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704988?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:40","pubTimestamp":1769676045,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,在重磅皮肤与哮喘药物Dupixent强劲销售表现的推动下,赛诺菲2025年第四季度盈利超出预期,并预测其营收和盈利在2026年将继续增长。在第四季度,Dupixent销售额同比增长32.2%至创纪录的42.46亿欧元,好于分析师预期,巩固了该药物作为赛诺菲业绩增长主要引擎的地位。目前的赛诺菲极度依赖其超级单品Dupixent。赛诺菲周四表示,将计提22.4亿欧元的减值费用,其中大部分与该药物有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"明星药物Dupixent销售额再创新高!赛诺菲(SNY.US)Q4盈利超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","SNY","IE00BFXG1179.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":-0.0192},{"period":"1month","weight":0.0423},{"period":"3month","weight":-0.0731},{"period":"6month","weight":-0.0814},{"period":"1year","weight":-0.1356},{"period":"ytd","weight":-0.1052}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司,专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织:DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.01689},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.017894},{"month":3,"riseRate":0.791667,"avgChangeRate":0.03072},{"month":4,"riseRate":0.625,"avgChangeRate":0.022233},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007253},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.015121},{"month":7,"riseRate":0.5,"avgChangeRate":0.015508},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007213},{"month":9,"riseRate":0.541667,"avgChangeRate":0.007782},{"month":10,"riseRate":0.541667,"avgChangeRate":-0.000294},{"month":11,"riseRate":0.583333,"avgChangeRate":-0.002306},{"month":12,"riseRate":0.666667,"avgChangeRate":0.029189}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}